Compounds > argatroban
Page last updated: 2024-12-08

argatroban

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID152951
CHEMBL ID59461
SCHEMBL ID4375
MeSH IDM0100029

Synonyms (22)

Synonym
BIDD:GT0748
2-piperidinecarboxylic acid, 1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-, (2r-(1(s*(r*)),2alpha,4beta))-
CHEMBL59461
(2r,4r)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(3r)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid
(21r)-argatroban
unii-0dw7mih1vx
0dw7mih1vx ,
cas-74863-84-6
dtxsid7046467 ,
tox21_112218
dtxcid5026467
(2r,4r)-1-[(2s)-5-[(diaminomethylidene)amino]-2-[(3r)-3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamido]pentanoyl]-4-methylpiperidine-2-carboxylic acid
SCHEMBL4375
tox21_112218_1
NCGC00166413-02
argatroban anhydrous, (21r)-
21r-argatroban anhydrous
argatroban anhydrous, 21r-
Q474880
21(r)-argatroban
EX-A4205
PD010129

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
Argatroban Action Pathway203

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency20.49470.000221.22318,912.5098AID1259243; AID1259247
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency13.80290.01237.983543.2770AID1645841
histone deacetylase 9 isoform 3Homo sapiens (human)Potency13.33320.037617.082361.1927AID1259364
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (33.33)24.3611
2020's6 (66.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 73.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index73.50 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index120.23 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (73.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (30)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective Randomized Pilot Trial on Safety and Feasibility of Argatroban as Anticoagulant in Patients With Extracorporeal Membrane Oxygenation (ECMO) [NCT05226442]Phase 2/Phase 340 participants (Anticipated)Interventional2021-12-01Recruiting
SAICoDis - Safety of Argatroban Infusion in Conduction Disturbances. A Prospective, Open, Multicenter Safety Study to Investigate Conduction Disturbances in Patients Receiving Argatroban Therapy. [NCT05740371]Phase 450 participants (Actual)Interventional2017-04-18Completed
Argatroban Combined With Antiplatelet Versus Antiplatelet for Acute Mild or Moderate Ischemic Stroke With Large-artery Atherosclerosis: a Prospective, Single Center Study [NCT03552354]Phase 4120 participants (Actual)Interventional2017-10-25Completed
Argatroban Plus R-tPA for Acute Ischemic Stroke: a Prospective, Random, Open Label, Blinded Assessment of Outcome Multi-center Study [NCT03740958]Phase 4808 participants (Actual)Interventional2018-12-21Completed
Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia [NCT00603824]Phase 40 participants (Actual)Interventional2008-01-31Withdrawn(stopped due to PI relocated)
ARTSS-IA: A Pilot, Phase IIa, Safety and Feasibility Study of ARgatroban in Combination With Recombinant Tissue Plasminogen Activator Stroke Study - Intra-Arterial [NCT02448069]Phase 210 participants (Actual)Interventional2015-05-31Completed
A Phase I, Open-Label, Randomized, Three-Period, Three-Sequence Crossover Study of the Effects of Co-administration of Intravenous VLX-1005 With Argatroban on Pharmacokinetics, Pharmacodynamics and Safety in Healthy Adult Subjects [NCT05325346]Phase 112 participants (Actual)Interventional2022-03-07Completed
Multi-arm Optimization of Stroke Thrombolysis (MOST): a Single Blinded, Randomized Controlled Adaptive, Multi-arm, Adjunctive-thrombolysis Efficacy Trial in Ischemic Stroke [NCT03735979]Phase 3514 participants (Actual)Interventional2019-10-15Active, not recruiting
An Open-label, Multi-centre, Clinical Study to Collect Information on the Clinical Use of Argatroban in Patients With Heparin Induced Thrombocytopenia (HIT) Type II Who Require Parenteral Antithrombotic Therapy [NCT00861692]Phase 220 participants (Actual)Interventional2009-04-30Completed
Open-Label, Randomised, Active Controlled, Multi-Centre Ph 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Acute HIT [NCT03809481]Phase 37 participants (Actual)Interventional2019-05-16Terminated(stopped due to Prolonged delay as a result of impact of Covid19 pandemic)
Argatroban Versus Lepirudin in Critically Ill Patients - A Randomized Double-blind Trial [NCT00798525]Phase 470 participants (Actual)Interventional2009-01-31Terminated(stopped due to Supply of Lepirudin ended on 01. April 2012, thus trial terminated on 31. March 2012)
A Pilot Trial to Assess the Efficacy of Argatroban (Argatra®) in Critically Ill Patients With Heparin Resistance [NCT01734252]Phase 244 participants (Actual)Interventional2012-07-29Completed
Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia. A Prospective Randomized Controlled Academic Single-centre Feasibility Study. [NCT01911624]Phase 294 participants (Actual)Interventional2013-01-31Completed
Phase 4 Study of Argatroban for Preventing Restenosis After Extracranial Vertebral Artery Stenting [NCT01980316]Phase 4114 participants (Actual)Interventional2010-04-30Completed
Monitoring Anticoagulation With Argatroban in Patients on Extracorporeal Membrane Oxygenation for Severe Lung Failure Using Anti-FIIa. Monitoring Anticoagulation With Unfractionated Heparin in Patients on Extracorporeal Membrane Oxygenation for Severe Lun [NCT06038682]100 participants (Actual)Observational2020-04-01Completed
InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19: A Prospective Randomized Study (The IMPACT Trial) [NCT04406389]Phase 414 participants (Actual)Interventional2020-10-13Terminated(stopped due to Low accrual)
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin [NCT00039858]Phase 424 participants Interventional2003-09-30Completed
A Randomised, Open, Parallel-group, Multicentre Study to Examine the Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Combination With Clopidogrel and Aspirin in Patients Undergoing Elective Percutaneous Coronary Intervention in C [NCT00508924]Phase 2140 participants (Actual)Interventional2005-08-31Completed
Open-Label Trial to Evaluate the Efficacy and Safety of the Use of Argatroban in Patients With Heparin-Induced Thrombocytopenia [NCT00198588]Phase 38 participants (Actual)Interventional2005-06-30Completed
ARTSS-2: A Pilot, Phase 2b, Randomized, Multi-center Trial of Argatroban in Combination With Recombinant Tissue Plasminogen Activator for Acute Stroke [NCT01464788]Phase 290 participants (Actual)Interventional2011-10-31Terminated(stopped due to The study was halted prematurely at 90 of 105 planned patients due to the beneficial results of embolectomy clinical trials.)
Effectiveness and Safety of Thromboprophylaxis After Surgery for Gynecologic Malignancy in China [NCT02935530]Phase 3315 participants (Actual)Interventional2016-01-31Completed
A Comparative Clinical and Pharmacoeconomic Study Comparing Argatroban® IV vs Desirudin SC for Patients With Suspected Heparin-Induced Thrombocytopenia (HIT)With or Without Thrombosis Syndrome (HIT/TS) [NCT00787332]Phase 416 participants (Actual)Interventional2008-09-30Terminated(stopped due to Low enrollment)
Phase 4 Study of Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting [NCT01163604]Phase 4114 participants (Actual)Interventional2010-08-31Completed
Systematische Dokumentation Von Patienten Mit Akutem HIT-Verdacht [NCT01304238]195 participants (Actual)Observational2009-02-28Completed
Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion [NCT01246011]Phase 49 participants (Actual)Interventional2010-11-30Terminated(stopped due to Enrollment was too slow.)
Pharmacokinetics and Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease (ESRD) Patients Undergoing Hemodialysis [NCT00035178]Phase 412 participants Interventional2002-05-31Completed
Efficacy of Argatroban in Acute Ischemic Stroke With Early Neurological Deterioration [NCT04275180]Phase 4628 participants (Actual)Interventional2020-03-21Completed
A Pilot Study To Determine The Safety Of Argatroban Injection In Combination With Tissue Plasmingen Activator (TPA) In Patients With Acute Ischemic Stroke [NCT00268762]Phase 1/Phase 265 participants (Actual)Interventional2003-02-28Completed
Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO: A Randomized Controlled Study [NCT04925167]174 participants (Anticipated)Interventional2021-07-06Recruiting
Argatroban Plus R-tPA for Acute Posterior Circulation Infarction (AR-PCI): a Prospective, Random, Blinded Assessment of Outcome and Open Label Multi-center Study [NCT03506009]Phase 43 participants (Actual)Interventional2018-07-11Terminated(stopped due to it is very difficult to recruit qualified patients)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00268762 (3) [back to overview]Arterial Complete Recanalization at 2 Hours Post tPA Bolus
NCT00268762 (3) [back to overview]Arterial Complete Recanalization at 24 Hours Post tPA Bolus
NCT00268762 (3) [back to overview]Symptomatic and Radiographic Intracerebral Hemorrhage
NCT00508924 (2) [back to overview]Activated Clotting Time (ACT) Value After the First Dosing of Study Treatment.
NCT00508924 (2) [back to overview]Composite and Each of Death, Myocardial Infarction, and Urgent Revascularisation at Day 30, and Major Bleeding Events During Hospital Stay.
NCT00787332 (1) [back to overview]New Thrombosis, Amputation, Death, Major and Minor Bleeding
NCT00861692 (7) [back to overview]All-cause Death
NCT00861692 (7) [back to overview]Composite of All-cause Death, Thrombosis (New and Extended) and Unplanned Amputation
NCT00861692 (7) [back to overview]Death Related to Heparin-induced Thrombocytopenia (HIT)
NCT00861692 (7) [back to overview]Number of Patients With Major or Minor Bleeding
NCT00861692 (7) [back to overview]Number of Patients With Platelet Count Recovery
NCT00861692 (7) [back to overview]Number of Patients With Thrombosis (New and Extended)
NCT00861692 (7) [back to overview]Number of Patients With Unplanned Amputation
NCT01163604 (1) [back to overview]Number of Participants With Occlusion and Restenosis at One Year
NCT01304238 (6) [back to overview]Number of Participants Diagnosed With Bleeding After the Occurrence of HIT II
NCT01304238 (6) [back to overview]Number of Participants Diagnosed With Thrombosis and/or Pulmonary Embolism After the Occurrence of HIT II
NCT01304238 (6) [back to overview]Number of Participants Who Experienced Skin Changes (Erythema and Necrosis) After the Occurrence of HIT II
NCT01304238 (6) [back to overview]Number of Participants Who Underwent Amputation After the Occurrence of HIT II
NCT01304238 (6) [back to overview]Number of Participants Who Were Diagnosed With Thrombocytopenia (Recurrent of Persistent) After the Occurrence of HIT II
NCT01304238 (6) [back to overview]Number of Participants With Fatal Complications After the Occurrence of HIT II
NCT01464788 (2) [back to overview]Number of Participants With 0 or 1 on Modified Rankin Scale
NCT01464788 (2) [back to overview]Number of Participants With Symptomatic Intracranial Hemorrhage Within 48 Hours of tPA Administration
NCT04406389 (4) [back to overview]30-day Mortality
NCT04406389 (4) [back to overview]Length of Intensive Care Unit (ICU) Stay in Days
NCT04406389 (4) [back to overview]Number of Documented Venous Thromboembolism (VTE), Arterial Thrombosis (Stroke, Myocardial Infarction, Other) and Microthrombosis Events
NCT04406389 (4) [back to overview]Number of Major and Clinically Relevant Non-major Bleeding Events

Arterial Complete Recanalization at 2 Hours Post tPA Bolus

Complete Recanalization as measured by either transcranial Doppler Ultrasound at 2 hours post tPA bolus. (NCT00268762)
Timeframe: 2 hours complete recanalization post tPA bolus

Interventionpercent of patients (Number)
Intervention40

[back to top]

Arterial Complete Recanalization at 24 Hours Post tPA Bolus

Complete recanalization at 24 hours post tPA bolus as measured by either transcranial Doppler ultrasound or CT-Angiography. (NCT00268762)
Timeframe: 24 hours from tPA bolus

Interventionpercent of patients (Number)
Intervention63

[back to top]

Symptomatic and Radiographic Intracerebral Hemorrhage

"Significant intracerebral hemorrhage as defined by either:~Symptomatic intracerebral hemorrhage or~Parenchymal hematoma type 2." (NCT00268762)
Timeframe: Within 7 days of enrollment

Interventionpercentage of patients (Number)
Intervention6.2

[back to top]

Activated Clotting Time (ACT) Value After the First Dosing of Study Treatment.

(NCT00508924)
Timeframe: 5 - 10 min after initial bolus

Interventionsecond (Median)
ARG250301.0
ARG300330.0
ARG350354.0
Heparin237.5

[back to top]

Composite and Each of Death, Myocardial Infarction, and Urgent Revascularisation at Day 30, and Major Bleeding Events During Hospital Stay.

"Composite end point (a): all cause death, myocardial infarction and urgent revascularization at Day30~Composite end point (b): all cause death, myocardial infarction and urgent revascularization at Day30 as well as major bleeding events during hospital stay" (NCT00508924)
Timeframe: 30 Days

,,,
Interventionparticipants (Number)
Composite end point (a)Composite end point (b)All cause deathMyocardial infarctionUrgent revascularizationMajor bleeding
ARG250110010
ARG300000000
ARG350110110
Heparin120101

[back to top]

New Thrombosis, Amputation, Death, Major and Minor Bleeding

(NCT00787332)
Timeframe: 30 days

Interventionparticipants (Number)
Desirudin1
Argatroban®5

[back to top]

All-cause Death

(NCT00861692)
Timeframe: During and 30 days after argatroban treatment

Interventionparticipants (Number)
Argatroban6

[back to top]

Composite of All-cause Death, Thrombosis (New and Extended) and Unplanned Amputation

(NCT00861692)
Timeframe: During and 30 days after argatroban treatment

Interventionparticipants (Number)
Argatroban10

[back to top] [back to top]

Number of Patients With Major or Minor Bleeding

"Major bleeding is defined as i) overt and associated with a fall in the haemoglobin level 2 g/dl or more, ii) leads to transfusion of 2 units or more, iii) is retroperitoneal, iv) occurs into a major prosthetic joint, or v) in intracranial.~Minor bleeding is defined as overt bleeding that does not meet the criteria of major bleeding." (NCT00861692)
Timeframe: During and 30 days after argatroban treatment

Interventionparticipants (Number)
Argatroban4

[back to top]

Number of Patients With Platelet Count Recovery

Platelet increase of ≥ 100G/L or 50%. (NCT00861692)
Timeframe: Day 3

Interventionparticipants (Number)
Argatroban12

[back to top]

Number of Patients With Thrombosis (New and Extended)

(NCT00861692)
Timeframe: During and 30 days after argatroban treatment

Interventionparticipants (Number)
Argatroban5

[back to top]

Number of Patients With Unplanned Amputation

(NCT00861692)
Timeframe: During and 30 days after argatroban treatment

Interventionparticipants (Number)
Argatroban0

[back to top]

Number of Participants With Occlusion and Restenosis at One Year

Stenosis detected by DSA(digital subtraction angiography),CTA(CT angiography)or MRA(MR angiography)was measured according to NASCET(North American Symptomatic Carotid Endarterectomy Trial)method.Concretely, NASCET stenosis is calculated from the ratio of the linear luminal diameter of the narrowest segment of the diseased portion of the artery to the diameter of the artery beyond any poststenotic dilatation: NASCET=(1-md/C)×100% (NCT01163604)
Timeframe: at one year

Interventionparticipants (Number)
Argatroban Group58
Non-argatroban Treated Group56

[back to top]

Number of Participants Diagnosed With Bleeding After the Occurrence of HIT II

Participants' medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). Bleeding was documented in the participant files. (NCT01304238)
Timeframe: 19 January 2005 to 25 October 2009

,,,,,,,,,
Interventionparticipants (Number)
No BleedingBleeding
Argatroban302
Argatroban/Danaparoid/Fondaparinux30
Argatroban/Fondaparinux110
Danaparoid433
Danaparoid/Argatroban83
Danaparoid/Fondaparinux50
Danaparoid/Fondaparinux/Lepirudin10
Danaparoid/Lepirudin22
Fondaparinux744
Lepirudin40

[back to top]

Number of Participants Diagnosed With Thrombosis and/or Pulmonary Embolism After the Occurrence of HIT II

Thrombosis is a clotting in a blood vessel. Pulmonary embolism is a clot, usually from the deep veins of the legs, carried away with the venous bloodstream into the lungs, where it may block pulmonary vessels. Participants' medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). (NCT01304238)
Timeframe: 19 January 2005 to 25 October 2009

,,,,,,,,,
Interventionparticipants (Number)
ThrombosisNo thrombosis or pulmonary embolismPulmonary embolismThrombosis and pulmonary embolismUnknown
Argatroban311000
Argatroban/Danaparoid/Fondaparinux30000
Argatroban/Fondaparinux110000
Danaparoid451000
Danaparoid/Argatroban64100
Danaparoid/Fondaparinux50000
Danaparoid/Fondaparinux/Lepirudin10000
Danaparoid/Lepirudin12100
Fondaparinux780000
Lepirudin40000

[back to top]

Number of Participants Who Experienced Skin Changes (Erythema and Necrosis) After the Occurrence of HIT II

Participants' medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). Erythema is a redness of the skin caused by hyperemia. Necrosis is the premature death of cells or tissues. (NCT01304238)
Timeframe: 19 January 2005 to 25 October 2009

,,,,,,,,,
Interventionparticipants (Number)
No skin changesSkin changes
Argatroban320
Argatroban/Danaparoid/Fondaparinux30
Argatroban/Fondaparinux110
Danaparoid451
Danaparoid/Argatroban110
Danaparoid/Fondaparinux50
Danaparoid/Fondaparinux/Lepirudin01
Danaparoid/Lepirudin31
Fondaparinux780
Lepirudin40

[back to top]

Number of Participants Who Underwent Amputation After the Occurrence of HIT II

Participants' medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). (NCT01304238)
Timeframe: 19 January 2005 to 25 October 2009

,,,,,,,,,
Interventionparticipants (Number)
No amputationAmputation
Argatroban320
Argatroban/Danaparoid/Fondaparinux30
Argatroban/Fondaparinux110
Danaparoid460
Danaparoid/Argatroban101
Danaparoid/Fondaparinux50
Danaparoid/Fondaparinux/Lepirudin10
Danaparoid/Lepirudin31
Fondaparinux780
Lepirudin40

[back to top]

Number of Participants Who Were Diagnosed With Thrombocytopenia (Recurrent of Persistent) After the Occurrence of HIT II

Participants' medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). Thrombocytopenia after HIT-II was documented in the participant files. (NCT01304238)
Timeframe: 19 January 2005 to 25 October 2009

,,,,,,,,,
Interventionparticipants (Number)
Recurrent thrombocytopeniaPersistent thrombocytopeniaNo thrombocytopenia
Argatroban0131
Argatroban/Danaparoid/Fondaparinux021
Argatroban/Fondaparinux0011
Danaparoid1144
Danaparoid/Argatroban308
Danaparoid/Fondaparinux005
Danaparoid/Fondaparinux/Lepirudin001
Danaparoid/Lepirudin103
Fondaparinux0078
Lepirudin004

[back to top]

Number of Participants With Fatal Complications After the Occurrence of HIT II

Participants' medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). A fatal complication is defined as a complication resulting in death. (NCT01304238)
Timeframe: 19 January 2005 to 25 October 2009

,,,,,,,,,
Interventionparticipants (Number)
No fatal complicationFatal complication
Argatroban275
Argatroban/Danaparoid/Fondaparinux30
Argatroban/Fondaparinux110
Danaparoid3511
Danaparoid/Argatroban92
Danaparoid/Fondaparinux50
Danaparoid/Fondaparinux/Lepirudin10
Danaparoid/Lepirudin22
Fondaparinux780
Lepirudin40

[back to top]

Number of Participants With 0 or 1 on Modified Rankin Scale

Excellent functional outcome as measured by the number of patients with a 0 or 1 on the modified Rankin Scale (mRS) at day 90 as assessed by study personnel blinded to treatment. (NCT01464788)
Timeframe: 90 days

Interventionparticipants (Number)
Low Dose Argatroban + Rt-PA9
High Dose Argatroban + Rt-PA10
Rt-PA (Alteplase)6

[back to top]

Number of Participants With Symptomatic Intracranial Hemorrhage Within 48 Hours of tPA Administration

Symptomatic intracranial hemorrhage (sICH) is defined as any evidence of bleeding on CT scan that in the opinion of the treating physician and/or an independent safety monitor is associated with a clinically significant neurological worsening. A four or more point increase in the NIHSS score from baseline (or last score obtained prior to blood found on CT scan) to subsequent CT scan at the time of potential worsening can be used as a guide by the clinical investigator or safety monitor for what represents a significant worsening in neurologic status but sICH can include any worsening deemed significant by the clinical investigator or independent safety monitor. (NCT01464788)
Timeframe: 48-hours

Interventionparticipants (Number)
Low Dose Argatroban + Rt-PA (Alteplase)4
High Dose Argatroban + Rt-PA (Alteplase)2
Rt-PA (Alteplase)3

[back to top]

30-day Mortality

Comparison of number of COVID-19 positive patients who have died within 30 days of starting treatment on each treatment arm (NCT04406389)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Intermediate Dose Prophylaxis0
Therapeutic Dose Anticoagulation2

[back to top]

Length of Intensive Care Unit (ICU) Stay in Days

Comparison of length of ICU stay in days between each treatment arm. (NCT04406389)
Timeframe: 6 months

InterventionDays (Median)
Intermediate Dose Prophylaxis25.5
Therapeutic Dose Anticoagulation25

[back to top]

Number of Documented Venous Thromboembolism (VTE), Arterial Thrombosis (Stroke, Myocardial Infarction, Other) and Microthrombosis Events

Comparison of number of documented VTE, arterial thrombosis and microthrombosis events on each treatment arm (NCT04406389)
Timeframe: 6 months

,
InterventionCount of Events (Number)
Venous Thromboembolism EventsArterial Thrombosis EventsMicrothrombosis Events
Intermediate Dose Prophylaxis110
Therapeutic Dose Anticoagulation001

[back to top]

Number of Major and Clinically Relevant Non-major Bleeding Events

Comparison of major and clinically-relevant non-major bleeding events on each treatment arm, as defined by the International Society of Thrombosis and Haemostasis (ISTH) criteria. (NCT04406389)
Timeframe: 6 months

,
InterventionCount of Events (Number)
Major Bleeding EventsClinically Relevant Non-Major Bleeding Events
Intermediate Dose Prophylaxis11
Therapeutic Dose Anticoagulation12

[back to top]
ConditionIndicatedRelationship StrengthStudiesTrials
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510